Opinion

Wolking v. Lindner

Court
District Court, M.D. Pennsylvania
Filed
May 3, 2024
Cited by
0 cases
Authority
More cited than 29.2%

The opinion

UNITED STATES DISTRICT COURT

MIDDLE DISTRICT OF PENNSYLVANIA

:

STACEY WOLKING and DARYL

WOLKING, :

Plaintiffs CIVIL ACTION NO. 3:23-cv-806

:

v. (JUDGE MANNION)

:

HENRY LINDNER and YOUNGS

APOTHECARY, INC., d/b/a :

TUNKHANNOCK

COMPOUNDING CENTER, :

Defendants :

MEMORANDUM

Plaintiffs, who claim that Defendant Tunkhannock Compounding

Center was negligent in its care of Stacey Wolking, (Doc. 1), have requested

from Defendant certain information relating to other patients, (Doc. 45), to

which requests TCC objects. (Doc. 46). The court ordered that the parties

submit supplemental briefing regarding this request, (Doc. 47), and they

have done so. (Doc. 48; Doc. 49).

I. THE CLAIMS

The Complaint alleges that Stacey Wolking met with Dr. Henry Lindner

once in person, and thereafter consulted him by email and phone, for advice

and treatment related to her symptoms of fatigue, brain fog, and malaise.

(Doc. 1 ¶9–11). Dr. Lindner diagnosed her with babesiosis, an infection

caused by a babesia parasite, “without ever confirming his diagnosis with a

blood smear examination or a PCR test,” which practice is “standard” for

doctors in the U.S. (Id. ¶12–16). He prescribed her a combination of

antimicrobial medications and corticosteroids. (Id. ¶¶20, 29). He also told

Stacey that he had diagnosed his daughter Valerie with babesiosis and had

developed the treatment program for her. (Id. ¶28).

Despite Stacey’s complaints of severe adverse side effects, Dr.

Lindner prescribed her increasingly higher dosages of corticosteroids, (Id.

¶¶31–60), often dosages significantly higher than a reasonable physician

would typically prescribe. (Id. ¶32). He informed Stacey that his daughter

Valerie had also taken high dosages of corticosteroids and had suffered

adverse side effects. (Id. ¶34, 37, 53).

During the course of this treatment, Lindner directed Stacey to fill her

prescriptions at TCC instead of her local pharmacy, telling her that her local

pharmacy might complain to the medical board about the high doses. (Id.

¶71). TCC provided Stacey “with the equivalent of 19,000 milligrams of

prednisone in a period of less than two months.” (Id. ¶74).

Defendants’ conduct “caused Stacey to suffer severe physical and

emotional pain and distress that she became suicidal, refused all medical

treatments, asked her doctors to allow her to die, and spent approximately

two days in hospice care at Loudoun Hospital” in Virginia. (Id. ¶75). Plaintiffs

claim that TCC provided Ms. Wolking with corticosteroid prescriptions “which

they knew or should have known were excessive, dangerous, inappropriate,

and/or improper”; that TCC did so “in violation of the rules, regulations,

practices, policies, and/or guidelines in place for the dispensing of

prescription corticosteroids by a licensed pharmacy”; and that it “failed to

exercise due diligence in its professional capacity” by not contacting Dr.

Lindner about the unreasonably high dosages, taking steps to correct his

error, or refusing to fill such prescriptions. (Id. ¶¶96–98).

Sadly, Dr. Lindner’s daughter Valerie passed away in December 2023.

(Doc. 30). Her obituary states that “[s]he lost her long battle with a tick-borne

disease.” (Doc. 31).

II. THE REQUEST

Plaintiffs requested that Defendant:

 [D]escribe the prescriptions written by Henry Lindner which were

filled at Tunkhannock Compounding Center in 2020, 2021, and

2022: the total number, the drug types and dosages, and the

amount billed and earned by Tunkhannock Compounding Center as

a result of these prescriptions. (Doc. 45-1 ¶12).

 [Produce the following]:

o All documents showing the corticosteroid prescriptions

dispensed to Valerie Lindner in 2021 and 2022, including

patient history documents and prescription documents. (Doc.

45-2 ¶1).

o Records in PK dispensing software showing manufacturer of

corticosteroids dispensed to Valerie Lindner and Stacey

Wolking in 2021 and 2022. (Id. ¶2).

o Any and all emails or other communication between Dr. Henry

Lindner and any TCC employee, in 2020 and the present,

concerning his babesiosis patients and/or corticosteroid

dosing and/or his treatment of Valerie Lindner for babesiosis.

(Id. ¶4).

o Any and all emails or other communications between TCC

employees in 2020 and the present, concerning Dr. Lindner’s

babesiosis patients and/or corticosteroid dosing and/or Dr.

Lindner’s treatment of Valerie Lindner for babesiosis. (Id. ¶5).

o Records or data showing total amounts of prednisone,

dexamethasone, and any other corticosteroid acquired and

dispensed by TCC in 2021 and 2022, and manufacturers or

each drug and entities from which they were acquired by TCC.

(Id. ¶6).

 [Designate officers authorized to testify as to]:

o Corticosteroid prescriptions dispensed to/for the benefit of

Valerie Lindner, (Doc. 45-3 ¶d);

o History of prescriptions written by Dr. Henry Lindner and filled

by TCC, including amounts earned by TCC from Dr. Lindner’s

prescriptions from 2013–2022, (Id. ¶e);

o Manufacturer of prednisone and dexamethasone dispensed

to Stacey Wolking and/or Valerie Lindner, identity of any entity

from which prednisone and dexamethasone were purchased

by TCC, (Id. ¶L);

o Total amounts of prednisone, dexamethasone, and any other

corticosteroid acquired and dispensed by TCC in 2021 and

2022, and manufacturers of each drug and entities from which

they were acquired by TCC, (Id. ¶m);

o Percentage of TCC revenue attributable to corticosteroids,

and to prescriptions written by Dr. Henry Lindner, in 2021 and

2022. (Id. ¶n).

(See Doc. 45). Defendant objects to these requests. (Doc. 46).

III. LEGAL STANDARD

Parties to a civil action “may obtain discovery regarding any

nonprivileged matter that is relevant to any party’s claim or defense and

proportional to the needs of the case, considering the importance of the

issues at stake in the action, the amount in controversy, the parties’ relative

access to the relevant information, the parties’ resources, the importance of

the discovery in resolving the issues, and whether the burden or expense of

the proposed discovery outweighs its likely benefit.” Fed. R. Civ. P. 26(b). A

request is relevant “if there is any possibility that the information may be

relevant to the general subject matter of the action.” Kegerise v.

Susquehanna Twp. Sch. Dist., Civ. No. 1:CV-14-0747, 2016 WL 2736048,

at *1 (M.D. Pa. May 11, 2016). “Information within the scope of discovery

need not be admissible in evidence to be discoverable.” Rule 26(b).

“A party may move for an order compelling disclosure or discovery.”

Fed. R. Civ. P. 37(a)(1). The initial burden is on the moving party to

demonstrate that the requested discovery falls within Rule 26(b)’s scope.

Schiavone v. Luzerne County, 243 F.R.D. 34, 37 (M.D. Pa. 2023). If this

burden is met, the nonmoving party must demonstrate that that the

requested discovery is not within Rule 26’s scope or is not sufficiently

relevant to justify the burden of producing it. Id.

IV. THE OBJECTIONS

TCC contends that the requested discovery is irrelevant, not

proportional to the needs of the case, privileged under the HIPAA Privacy

Rule, and not discoverable under Pennsylvania law. (Doc. 48 at 7–10).

Because information protected by the Privacy Rule may be disclosed

pursuant to a court order, 45 C.F.R. §164.512(f)(1)(ii)(A), the court need not

address that ground of objection again. (See Doc. 47 at 3).

A. Relevance

TCC asserts that because Valerie Lindner is not a party to this case,

her treatment and prescriptions are not at issue and thus not relevant to

Plaintiffs’ claims or defenses. (Doc. 48 at 7).

B. Proportionality

TCC also submits that Plaintiffs’ request is not proportional to the

needs of the case “because it does not assist in what’s at stake in the action,

i.e., the cause of Ms. Wolking’s damages stemming from her alleged

treatment by Dr. Lindner and the importance reaching that conclusion.” (Doc.

48 at 8). It argues that the requested information will not make more or less

likely any fact pertaining to “the liability and cause of Ms. Wolking’s

damages.” (Id. at 8). TCC further asserts that “there is nothing to establish

that babesiosis or the treatment of the disease was the cause of, or even

related to, Ms. Lindner’s death,” and so making comparison between her and

Stacey Wolking “would be highly speculative and based on conjecture.” (Id.

at 8).

C. Pennsylvania law

Other federal courts have applied Pennsylvania law regarding

discovery of medical records in diversity cases, see Peronis v. United States,

2:16-cv-1389, 2017 WL 3705058, at *2 (W.D. Pa. Aug. 28, 2017); Creely v.

Genesis Health Ventures, Inc., No. Civ. 04-cv-679, 2004 WL 2943661, at

**3–4 (E.D. Pa. Dec. 17, 2004), and Plaintiffs do not dispute that it applies.

(Doc. 49 at 14–15).

Defendant references the balancing test that has been applied in

evaluating a request for medical information, see Lykes v. Yates, 77 A.3d

27, 31 (Pa. Super. Ct. 2013), but does not advance a position as to what

result that test yields here. (Doc. 48 at 910). It also relies on Buckman v.

Verazin, 54 A.3d 956, 964 (Pa. Super. Ct. 2012) for the proposition that “[a]ny

information related to third parties that have not given their consent is

confidential and not relevant to this negligence claim against Tunkhannock.”

(Doc. 48 at 10).

V. PLAINTIFFS’ ARGUMENT

A. Relevance

Plaintiffs submit that the prescriptions written by Dr. Lindner between

2013 and 2022 are relevant to (1) evaluate the conflicting testimony of

Lindner and Courtney Young of TCC as to whether TCC spoke to Lindner

about Ms. Wolking’s prescriptions; (2) to assess the financial impact of

Lindner’s prescriptions and thus the motive of TCC to challenge his

decisions; (3) to assess Young’s conduct in consulting Dr. Lindner about Ms.

Wolking’s prescriptions; and (4) to assess the pharmacists’ knowledge of

safe dosages by reading the package inserts provided by manufacturers.

(Doc. 49 at 3–8). As to its requests for communications related to other

patients, Plaintiffs assert that such information is relevant to their “theory that

TCC established a pattern and practice based on information about other

patients” and to the pharmacists’ knowledge about babesiosis and the risks

of corticosteroid prescriptions. (Id. at 8).

B. Proportionality

As to proportionality, Plaintiffs argue that the burden and expense

involved in producing such discovery would be minimal, because TCC has

access to its own data and Young has testified that corticosteroid

prescriptions were not a large aspect of TCC’s business. (Doc. 49 at 11).

According to Plaintiffs, “[t]he minimal burden involved is appropriate in a case

where TCC’s negligence nearly killed Ms. Wolking and has injured her for

life.” (Id. at 12).

C. Pennsylvania Law

With regard to Defendant’s argument about the application of

Pennsylvania law to discovery of confidential medical information, Plaintiffs

contend that disclosure of Valerie Lindner’s information would not harm any

physician-patient relationship because she is deceased. They further

suggest that identifying information about other patients can be redacted.

(Doc. 49 at 14 (quoting Roth v. Sunrise Senior Living Mgmt., Inc., No. 2:11-

cv-4567, 2012 WL 748401, at *2 (E.D. Pa. Mar. 8, 2012) (“Pennsylvania state

privacy laws do not preclude disclosure of the redacted medical records in

this case.”)).

D. Patient profile

Finally, Plaintiffs reiterate their request for Ms. Wolking’s “patient

profile.” (Doc. 49 at 9). Though Defendant mentions this request in its

supplemental brief, (Doc. 48 at 2), it offers no objection thereto.

VI. DISCUSSION

The court finds that Plaintiffs have satisfied their burden of

demonstrating that the requested discovery is within the scope of Rule 26(b).

The requested information about prior corticosteroid prescriptions filled by

TCC, manufacturer information, and communications concerning babesiosis

patients and/or corticosteroid dosing, even if related to other patients, may

be relevant to Plaintiffs’ claim that TCC was negligent in its care of Stacey

Wolking. Such information could indicate that the pharmacists were on notice

of the proper dosages or could aid in evaluating testimony regarding their

consultations with Dr. Lindner regarding high dosages. And given the serious

nature of the allegations here and the minor burden on Defendant to produce

a portion of its own information, the court finds that the request is proportional

to the needs of the case.

With respect to Valerie Lindner’s medical information, the court finds

that a privacy interest does not outweigh the need for disclosure because

Ms. Lindner is deceased and Dr. Lindner has testified about her medical

history. As to other patients’ information, redaction will adequately ameliorate

the concern of privacy intrusion. Finally, the court finds that Plaintiffs’ request

for Plaintiff Stacey Wolking’s “patient profile” is relevant and proportional to

the needs of the case. Accordingly, Plaintiffs’ requests are within the scope

of Fed. R. Civ. P. 26(b)(1), and Defendant must fulfill them.

The court advises the parties that this memorandum does not opine on

the admissibility of the requested information at trial.

VII. CONCLUSION

For the foregoing reasons, the court concludes that Plaintiffs’ discovery

requests are within the scope of Federal Rule 26(b)(1). It will therefore order

that Defendant fulfill these requests. Such order follows.

s/ Malachy E. Mannion

MALACHY E. MANNION

United States District Judge

DATE: May 3, 2024

23-806-02

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.